IL284868A - Mutant polypeptides of interleukin-34 (il-34) and their use for medical treatment - Google Patents

Mutant polypeptides of interleukin-34 (il-34) and their use for medical treatment

Info

Publication number
IL284868A
IL284868A IL284868A IL28486821A IL284868A IL 284868 A IL284868 A IL 284868A IL 284868 A IL284868 A IL 284868A IL 28486821 A IL28486821 A IL 28486821A IL 284868 A IL284868 A IL 284868A
Authority
IL
Israel
Prior art keywords
polypeptides
therapy
interleukin
mutated
mutated interleukin
Prior art date
Application number
IL284868A
Other languages
English (en)
Hebrew (he)
Inventor
Carole Guillonneau
Ignacio Anegon
Erwan Mortier
Agnes Quemener
Original Assignee
Inst Nat Sante Rech Med
Univ Nantes
Carole Guillonneau
Ignacio Anegon
Erwan Mortier
Agnes Quemener
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Nantes, Carole Guillonneau, Ignacio Anegon, Erwan Mortier, Agnes Quemener filed Critical Inst Nat Sante Rech Med
Publication of IL284868A publication Critical patent/IL284868A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2334—Interleukin-34 (IL-34)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
IL284868A 2019-01-15 2021-07-14 Mutant polypeptides of interleukin-34 (il-34) and their use for medical treatment IL284868A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305046 2019-01-15
PCT/EP2020/050920 WO2020148338A1 (en) 2019-01-15 2020-01-15 Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy

Publications (1)

Publication Number Publication Date
IL284868A true IL284868A (en) 2021-08-31

Family

ID=65228484

Family Applications (1)

Application Number Title Priority Date Filing Date
IL284868A IL284868A (en) 2019-01-15 2021-07-14 Mutant polypeptides of interleukin-34 (il-34) and their use for medical treatment

Country Status (12)

Country Link
US (1) US20220098264A1 (US07655688-20100202-C00086.png)
EP (1) EP3911670A1 (US07655688-20100202-C00086.png)
JP (1) JP2022517029A (US07655688-20100202-C00086.png)
KR (1) KR20210121077A (US07655688-20100202-C00086.png)
CN (1) CN113508129A (US07655688-20100202-C00086.png)
AU (1) AU2020208909A1 (US07655688-20100202-C00086.png)
BR (1) BR112021013944A8 (US07655688-20100202-C00086.png)
CA (1) CA3126741A1 (US07655688-20100202-C00086.png)
IL (1) IL284868A (US07655688-20100202-C00086.png)
MX (1) MX2021008525A (US07655688-20100202-C00086.png)
SG (1) SG11202107606VA (US07655688-20100202-C00086.png)
WO (1) WO2020148338A1 (US07655688-20100202-C00086.png)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115819614B (zh) * 2022-06-21 2024-02-23 四川大学华西医院 一种基于il34的嵌合抗原受体免疫细胞制备及其应用
WO2023246908A1 (zh) * 2022-06-21 2023-12-28 四川大学华西医院 靶向csf1r的嵌合抗原受体免疫细胞制备及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR520E (fr) 1901-11-13 1903-01-26 Bermont Victor Etienne Procédé industriel d'extraction directe du zinc contenu dans les minerais oxydés, et plus spécialement dans la smithsonite (znco3) et la calamine (h2zn2sio5)
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
EP0465529B1 (en) 1989-03-21 1998-04-29 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
ES2338791T3 (es) 1992-08-21 2010-05-12 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
EP0689601B1 (en) 1993-02-22 2006-10-04 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
EP0753069A1 (en) 1994-04-15 1997-01-15 Targeted Genetics Corporation Gene delivery fusion proteins
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
JP3793693B2 (ja) 1998-12-23 2006-07-05 ファイザー インコーポレーテッド Ｃｔｌａ−４に対するヒトモノクローナル抗体
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
KR100996759B1 (ko) 1999-08-24 2010-11-25 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
EP1935427B1 (en) 2000-07-03 2018-03-07 Bristol-Myers Squibb Company Uses of soluble CTLA4 mutant molecules
EP1435910B9 (en) 2001-10-19 2010-02-03 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
ATE540978T1 (de) 2002-10-17 2012-01-15 Genmab As Humane monoklonale antikörper gegen cd20
ATE514713T1 (de) 2002-12-23 2011-07-15 Wyeth Llc Antikörper gegen pd-1 und ihre verwendung
AU2005267062C1 (en) * 2004-07-22 2013-01-17 Five Prime Therapeutics, Inc. Compositions and methods of use for MGD-CSF in disease treatment
EP2439272A3 (en) 2005-05-09 2013-07-31 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
BRPI0613361A2 (pt) 2005-07-01 2011-01-04 Medarex Inc anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
US8476239B2 (en) 2005-12-20 2013-07-02 Bristol-Myers Squibb Company Stable protein formulations
MX2010008786A (es) 2008-02-11 2010-12-01 Curetech Ltd Anticuerpos monoclonales para tratamiento de tumores.
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CA2734908A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
CN102203125A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
KR20220047668A (ko) 2008-12-09 2022-04-18 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
US8345509B2 (en) 2009-04-16 2013-01-01 Chevron U.S.A., Inc. System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP2581113B1 (en) 2010-06-11 2018-05-09 Kyowa Hakko Kirin Co., Ltd. Anti-tim-3 antibody
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
EP3763741A1 (en) 2011-11-28 2021-01-13 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
BR112015021999A8 (pt) 2013-03-15 2019-12-03 Bristol Myers Squibb Co inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase
KR20160081898A (ko) 2013-09-06 2016-07-08 오리진 디스커버리 테크놀로지스 리미티드 면역조절제로서 1,3,4-옥사디아졸 및 1,3,4-티아디아졸 유도체
HUE048874T2 (hu) 2013-09-06 2020-08-28 Aurigene Discovery Tech Ltd 1,2,4-oxadiazol-származékok, mint immunmodulátorok
WO2016009041A1 (en) * 2014-07-17 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) An isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases
CN106084030B (zh) * 2016-04-25 2019-11-08 北京大学 一种提高白细胞介素il-34热稳定性的方法

Also Published As

Publication number Publication date
CN113508129A (zh) 2021-10-15
KR20210121077A (ko) 2021-10-07
SG11202107606VA (en) 2021-08-30
BR112021013944A2 (US07655688-20100202-C00086.png) 2021-11-21
CA3126741A1 (en) 2020-07-23
AU2020208909A1 (en) 2021-07-29
MX2021008525A (es) 2021-11-12
BR112021013944A8 (pt) 2023-02-07
US20220098264A1 (en) 2022-03-31
EP3911670A1 (en) 2021-11-24
WO2020148338A1 (en) 2020-07-23
JP2022517029A (ja) 2022-03-03

Similar Documents

Publication Publication Date Title
IL304469A (en) Reengineered tnpb proteins and their uses
IL284633A (en) Polypeptides containing modified IL-2 peptides and uses thereof
IL265489B (en) Recombinant binding proteins and their uses
IL287781A (en) Clec-12a binding polypeptides and uses thereof
IL284868A (en) Mutant polypeptides of interleukin-34 (il-34) and their use for medical treatment
IL283241A (en) High potency transgenic tm-phytase polypeptides and their fragments
IL287782A (en) 33cd-binding polypeptides and their uses
IL280808A (en) OX40-binding polypeptides and their uses
IL261397A (en) Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy
SG10201912408WA (en) Chimeric polypeptides and methods of altering their localisation in the cell membrane
EP3813861A4 (en) HEPARIN-ASSOCIATED POLYPEPTIDES AND THEIR USES
GB201819200D0 (en) Polypeptide and uses thereof
GB202201003D0 (en) Fusion polypeptide and use thereof
EP3816186A4 (en) PD-L1 BINDING POLYPEPTIDE AND USE
GB2600592B (en) Polypeptide and use thereof
GB2603645B (en) Polypeptides having anti-senescent effects and uses thereof
GB202201004D0 (en) Reconbinant fusion polypeptide and use thereof
IL313778A (en) LILRB polypeptides and their use
EP3684796A4 (en) SUCCINATE REGULATORY POLYPEPTIDES AND USES
EP3425054C0 (en) CYTOCHROME MUTANT PROTEIN AND ITS USE
GB202109082D0 (en) Polypeptides and uses thereof
EP3611181A4 (en) ATP1A1T TARGETING POLYPEPTIDE AND USES
EP4103586A4 (en) POLYPEPTIDES AND THEIR USE
IL275241A (en) - Engineered glycosylation in recombinant polypeptides and uses thereof
EP3947418C0 (en) PEPTIDES AND THEIR USE